Continuous Positive Airway Pressure for Obstructive Sleep Apnea
Study Summary
This trial will study whether CPAP is an effective treatment for obstructive sleep apnea in patients with polycythemia vera or essential thrombocythemia.
- Obstructive Sleep Apnea
- Polycythemia Vera
- JAK2 Gene Mutation
- Essential Thrombocythemia
- CALR Gene Mutation
- MPL Gene Mutation
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: Baseline, after 3 months, and after 6 months on trial
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Cohort I (observation)
1 of 2
Cohort II: (CPAP treatment)
1 of 2
Active Control
Experimental Treatment
72 Total Participants · 2 Treatment Groups
Primary Treatment: Continuous Positive Airway Pressure · No Placebo Group · Phase < 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 30 - 85 · All Participants · 13 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is the age restriction for this trial limited to those aged 55 or younger?
"The eligibility criteria for this medical trial includes a minimum age of 30 and an upper limit of 85." - Anonymous Online Contributor
Could you please provide an estimate of the participants in this clinical research?
"Affirmative, the research documentation found on clinicaltrials.gov attests to this medical trial's patient search commencing in May of 2019 and recently updated in June 2022. 72 individuals need to be recruited from two distinct locations." - Anonymous Online Contributor
What criteria must participants fulfill to enter this clinical study?
"This trial is currently accepting 72 adults between the ages of 30-85 with polycythemia vera. To qualify for participation, individuals must have a ≤ 20 pack/year smoking history or quit >= 3 years ago without any COPD symptoms and normal pulmonary health; an ECOG performance status 0-2; negative pregnancy tests if applicable; highly effective contraception to reduce risk of conception until at least three months after treatment ends; ability to provide informed consent and sign approved forms conforming to federal guidelines; capability of reading and completing study questionnaires; eligible OSA screening component results which entail having sleep studies score ≥ 5 indicating OSA diagnosis" - Anonymous Online Contributor
Are there any vacant slots for participants in this research study?
"As detailed on clinicaltrials.gov, this research is currently seeking participants. It was initially listed on May 15th 2019 and updated most recently in June 7th 2022." - Anonymous Online Contributor